Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RG1068 in OCD
NCT00216294Phase 2Completed
- Sponsor
- Indiana University School of Medicine
- Start
- Feb 2005
- Primary completion
- Apr 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lobeglitazone in obsessive compulsive disorder (OCD) (2 arms), sponsored by Indiana University School of Medicine. Primary endpoints: Yale-Brown Obsessive Compulsive Scale and Clinical Global Impression of Change Scale. Started Feb 2005; status: completed.
02
Drugs
lobeglitazone
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on NCT00216294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00216294.